Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

Posted on by Pencis

Prof. Dr. Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

The First Medical Center, Chinese PLA General Hospital | China

AUTHOR PROFILE

ORCID ID

🌟YUNSHENG YANG, M.D. – A LEADER IN GASTROENTEROLOGY 🏥

🎓EARLY ACADEMIC PURSUITS 

Dr. Yunsheng Yang earned his M.D. from the First Military Medical University in 1995, laying the foundation for his illustrious medical career. He pursued postdoctoral training at the Fourth Military Medical University in China, further honing his expertise in gastroenterology. His academic journey extended internationally with visiting scholar positions at the University of Sydney’s Westmead Hospital in 2008 and Mayo Clinic Rochester in 2014, where he gained invaluable global exposure to advanced medical practices.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently, Dr. Yang serves as the Academic Director of the Department of Gastroenterology and Hepatology at the First Medical Center, Chinese PLA General Hospital (PLAGH, 301 Hospital) in Beijing, China. His leadership extends beyond national borders, with visiting or adjunct professorships at Shenzhen University, Universitas Amoiensis, and the University of Michigan, USA.

His involvement in prestigious medical societies includes being the immediate past president of the Chinese Society of Gastroenterology and the Director of the APSDE Training Center in PLAGH since 2006. Dr. Yang actively engages with the World Gastroenterology Organization (WGO), serving as a scientific committee member and having previously contributed to the WGO Endoscopy Group and Nomination Committee.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

Dr. Yang’s clinical expertise primarily revolves around gastrointestinal (GI) disorders and therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP). His research is focused on robot-assisted endoscopy and GI microbiota, where he has pioneered multiple innovative procedures in China, including:

  • Endoscopic suturing for GERD (2001)
  • Double balloon enteroscopy (2003)
  • Peroral video cholangioscopy and laser lithotripsy (2004)
  • Confocal endomicroscopy (2006)
  • MUSE for GERD (2017)
  • Fecal Microbiota Transplantation (FMT) clinical trials for IBD, autism, and Tourette syndrome (since 2014)

Notably, he led the development of the YunSRobot, a robot-assisted GI endoscopy system, successfully performing gastroscopy on human volunteers in 2017 and completing remote gastroscopy in 2021. These groundbreaking achievements have been published and indexed in PubMed.

📚IMPACT AND INFLUENCE 

Dr. Yang’s influence in the field of gastroenterology is reflected in his extensive publication record. He has authored over 200 articles in Chinese journals and more than 150 papers in international SCI-indexed journals, including prestigious titles such as Gastroenterology, Hepatology, The American Journal of Gastroenterology (AJG), Gastrointestinal Endoscopy (GIE), Alimentary Pharmacology & Therapeutics (AP&T), and Gut.

As an editorial board member for Gut and AP&T, and associate editor for MMR and JDD, he continues to shape the direction of gastroenterology research and clinical practice worldwide.

🌟ACADEMIC CITES AND RECOGNITION 

Dr. Yang’s research contributions have been extensively cited by peers in the medical and scientific communities. His innovations in endoscopic procedures and gastrointestinal microbiota research have influenced treatment protocols and technological advancements in digestive health worldwide. His pioneering work on FMT for neurological conditions and robotic-assisted endoscopy is setting new standards in precision medicine.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Dr. Yang’s enduring legacy lies in his transformative impact on gastroenterology, blending cutting-edge technology with clinical expertise. His leadership in developing robotic-assisted endoscopy has the potential to revolutionize non-invasive diagnostics and treatment, paving the way for AI-integrated endoscopic procedures.

Looking ahead, Dr. Yang continues to push the boundaries of GI research, particularly in the integration of robotics, microbiota-based therapies, and novel endoscopic interventions. His mentorship of young gastroenterologists ensures a lasting impact on the field, fostering the next generation of leaders in digestive health research and clinical innovation.

🌍CONCLUSION 

Dr. Yunsheng Yang stands as a trailblazer in the field of gastroenterology, with his extensive contributions in clinical practice, research, and technological innovation. His groundbreaking advancements in robot-assisted endoscopy and GI microbiota research have set new benchmarks in the medical field. His dedication to patient care, scientific discovery, and mentorship ensures his influence will resonate for years to come, shaping the future of digestive health worldwide.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.
    Authors: Yan J, Chen H, Zhang Y, Peng L, Wang Z, Lan X, Yu S, Yang Y.
    Year: 2024

 

  1. Title: Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Authors: Chen J, Zhang Y, Min H, Zhi J, Ma S, Dong H, Yan J, Chi X, Zhang X, Yang Y.
    Year: 2024

 

  1. Title: Colorectal cancer and gut microbiota studies in China.
    Authors: Wang Z, Dan W, Zhang N, Fang J, Yang Y.
    Year: 2023

 

  1. Title: The fecal microbiota from children with autism impact gut metabolism and learning and memory abilities of honeybees.
    Authors: Li Y, Zhang Y, Luo X, Meng Y, Zhong Z, Zheng H, Yang Y.
    Year: 2023

 

  1. Title: Deep insights into the gut microbial community of extreme longevity in South Chinese centenarians by ultra-deep metagenomics and large-scale culturomics.
    Authors: Li C, Luan Z, Zhao Y, Chen J, Yang Y, Wang C, Jing Y, Qi S, Li Z, Guo H, et al.
    Year: 2022

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Posted on by Pencis

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Nankai University | China

Author Profile

Scopus

Orcid ID

📚 Prof. Tao Sun: Innovator in Oncology and Drug Development

🎓Position:

  • Professor and Doctoral Supervisor, College of Pharmacy, Nankai University, China 🎓

🌟Titles and Awards:

  • National Youth Talent 🌟
  • Winner of the Tianjin Distinguished Youth Scholar 🏆

🔬Research Focus:

  • Molecular mechanisms of malignant tumors 🧬
  • Drug development 💊
  • Pharmacology 🔬

📄Publications:

  • Over 40 papers in prestigious journals, including Advanced Materials, Science Translational Medicine, Hepatology, and Cancer Research, as the first or corresponding author. 📄

📜Patents and Approvals:

  • More than 20 authorized patents 📜
  • 3 new drug clinical approvals ✅

🧪Research Leadership:

  • Principal investigator of 8 major scientific research projects, including Major National Science and Technology Projects and general projects of the National Natural Science Foundation of China. 🧪

🥇Achievements in Education:

  • Instructed students to win the Gold Award in the China International College Students’ “Internet+” Innovation and Entrepreneurship Competition 🥇
  • Recipient of the “Top Ten Award of Scholarly Mentor and Beneficial Friend” at Nankai University 🎖
  • Second Prize winner of the Nankai University Teaching Achievement Award 🥈

💊Summary:

  • Prof. Tao Sun is a distinguished scholar and innovator at Nankai University, renowned for his contributions to oncology, drug development, and pharmacology. His prolific research, numerous patents, and leadership in significant scientific projects underscore his impact in the field. As an educator, he has been instrumental in guiding students to achieve excellence, earning recognition for his mentorship and teaching achievements. 🌟🔬💊

 

📊🔬Notable Publication:

 

Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1

  • Authors: Cai, S., Bi, Z., Bai, Y., … Liu, H., Yang, C.
    Journal: Frontiers in Oncology
  • Year: 2020

 

Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin

  • Authors: Meng, J., Han, J., Wang, X., … Liu, H., Sun, T.
    Journal: Pharmacological Research
  • Year: 2023

 

Correction: Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma

  • Authors: Han, J., Meng, J., Chen, S., … Sun, T., Yang, C.
    Journal: Cancer Research
  • Year: 2019

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.